pancreatic cancer can be difficult to diagnose because symptoms — which include jaundice, abdominal or upper back pain, unexplained weight loss and fatigue, among others — may not be present in the early stages, only arriving once tumours begin to have an effect on the body. signs of the aggressive cancer can also vary depending on the precise location of tumours, making diagnosis a frustrating ordeal for patients.
in an attempt to improve the odds of the deadly disease, researchers gave mebendazole to mice that were engineered to develop pancreatic cancer while measuring inflammation levels, tissue change and the stage, grade and metastatic status of any tumours. the drug, which was originally intended to eradicate roundworm and hookworm by starving the parasitic infections of sustenance, appears to have a similar effect on cancer cells. mebendazole works by halting the production of tubulin — a micro-skeleton of the inner cell and a pathway used for transport — causing parasites and cancer cells to begin to collapse from within.
the vast potential of the drug on all stages of pancreatic cancer has riggins and his team eager to begin human trials as soon as possible.
“we are advocating for use of mebendazole as a therapy for those diagnosed before metastasis to see if we can slow or prevent pancreatic cancer,” he said. “for those with more advanced cancers, it could be an alternative to certain surgeries. mebendazole may have utility as a therapy after initial treatment to prevent tumour recurrence in the 15 to 20 per cent of pancreatic adenocarcinoma patients who undergo surgery.